Long-term Follow up Local Registry Study of Kymriah in South Korea

This study will inform on long-term real-world safety and effectiveness of tisagenlecleucel. The primary objective is to evaluate the long-term safety and the risk of secondary malignancies in patients with B lymphocyte malignancies treated with tisagenlecleucel in a real-world setting. The main secondary objective is to evaluate the longterm effectiveness of tisagenlecleucel. All participants enrolled in this study will be followed up for 15 years from the time of Kymriah® infusion.